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indirect method of estimating intra-fraction motion, because it is based on the comparison of prostate position on two EPID of
Mv: Before and immediately after the session ends. The position of the gold markers on each daily pair of EPIs was compared
to their intended position, as seen on the reference DRR, to determine isocenter placement error, by using the marker matching
functions. Patients were treated in the supine position using IMRT. The prescription dose was 76Gy in 38 fractions. The PTV was
required to be covered by 95% of the prescription dose. The mean intrafraction motion (±SD) was 0.02±0.19 cm, 0.11±0.18 cm
and 0.11±0.16 cm along the L–R, S–I and A–P axes respectively. If all pre-treatment isocenter placement errors have fully were
completely corrected, leaving intra-fraction motion as the only variable affecting during-treatment isocenter placement, PTV
margins of 0.36 cm, 0.36 cm and 0.26 cm would be required along the L–R, S–I and A–P axes respectively, to give a 95% probability
of complete CTV coverage on any given treatment day. Concluding, while our estimates of CTV to PTV margin requirements
along the L–I and S–I axes are comparable to other reports, our estimate of margin requirement along the A–P axis appears to be
slightly less than in the other reports using image guidance.
http://dx.doi.org/10.1016/j.rpor.2013.03.499
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The combination of transurethral resection of the bladder, chemotherapy and radiation therapy is a validated approach to bladder
preservation in cancer muscle-invasive. However there is very little information on the patterns of treatment with radiotherapy.
The aim of this study was to assess therapeutic approaches to muscle-invasive bladder cancer at Radiation Oncology Services
in Spain. A speciﬁcally designed questionnaire was submitted to 86 Radiation Oncology Services in Spain through the SEOR
and URONCOR via e-mail in 2010, to assess their therapeutic approach to bladder cancer over the 2005–2009 period. A total of 26
centers (30.5% of the total, ofwhich 96%were public and 81%were university hospitals) answered the questionnaire. 92% reported
to have a Urology Tumor Board that makes consensual decisions on muscle-invasive bladder carcinomas. Treatment approaches
was reported to be systematically determined by the Board at 92%. A total of 100% of hospitals provide radical 3D conformal
radiation therapy and three hospitals also performed IMRT. The radiation therapy scheme designed for “bladder preservation”
was reported to include both options: single-dose series (continuous irradiation without response evaluation after 40–45Gy) or
fractionated series (irradiation with response evaluation by cystoscopy and by radical transurethral resection after 40–45Gy). A
total of 64% of hospitals “always” perform single-dose series, of which 19% “sometimes” perform fractionated series. Twenty
percent (ﬁve hospitals) “exclusively” perform fractionated series, with an average response evaluation interval of seven days.
The average of patients on radical radiation therapy in 2005 was 51%; 47% in 2008, and 43% in 2009, with a statistically signiﬁcant
decreasing tendency (p=0.02). At public hospitals in Spain, there are multidisciplinary urology tumor boards where urologists,
radiation oncologists and medical oncologists collaborate to systematically make consensual decisions. In this period there is a
signiﬁcant downward trend in the use of radiotherapy for bladder sparing.
http://dx.doi.org/10.1016/j.rpor.2013.03.500
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Purpose. Postoperative radiotherapy in prostate cancer patients treated with prostatectomy improves biochemical progression-
free survival (BPFS) and in selected patients prolongs the overall survival. Pelvic IMRT in this group of patients has been poorly
explored regarding acute and late toxicity compared with 3DCRT. We retrospectively analyze patients treated in our institution
with IMRT after prostatectomy.
Material and methods. Patients with pT3-T4 and/or N+ and/or positive surgical margin received adjuvant IMRT (aIMRT). Patients
with biochemical failure (PSA>0.1ng/ml) after prostatectomy were treated with salvage IMRT (sIMRT). Dose-range administered
was 64–72Gy in 30–33 fractions. High-risk or very high-risk patients received long-term androgen deprivation therapy.
Results. Ninety-six patients were analyzed, 34 were treated with aIMRT and 62 patients sIMRT. All patients completed the treat-
ment protocol. The median time intervals from surgery to aIMRT and sIMRT were 3-months and 19.5-months, respectively.
Adverse events were recorded following the CTCAE v4.0 score. Grade 1–2 and grade 3–4 acute GU toxicity were observed in 52
patients (54.2%) and 1 patient (1.0%), respectively. Thirty-seven patients (38.5%) had grade 1–2 acute GI toxicity and no patient
with grade 3–4 GI complications was recorded. Eighty-ﬁve patients were evaluated for late complications and grade 1–2 chronic
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GU toxicity was observed in 16 patients (19.0%) and 2 patients (2.4%) had grade 3–4 GU adverse effects. Grade 1–2 late GI toxi-
cities were presented in 6 patients (7.1%) and no patient had grade 3–4 late GU toxicity. After a median follow-up of 70-months,
the median BPF and 5-year BPFS in the groups treated with aIMRT and sIMRT were 114-months/88% and not-reached/80%,
respectively.
Conclusion. The proﬁle of acute and late adverse effects in prostatectomy patients treated with aIMRT or sIMRT is compared
favorably with 3DCRT series. Further follow-up and the inclusion of a greater number of patients are needed to assess the
deﬁnitive effect of aIMRT or sIMRT in late toxicity, biochemical failure and overall survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.501
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Purpose/objective. To review the criteria followed by urology departments to refer patients to postoperative External Beam Radio-
therapy (EBRT) for localized prostate cancer (PCa) after Radical Prostatectomy (RP).
Material/methods. Data from 159 consecutive patients referred from 4 different urology departments, were collected between
2007 and 2012. Clinical and pathological data were analyzed, including a double risk-group classiﬁcation before and after PR,
postoperative EBRT criteria, time from indication to EBRT and pre-EBRT PSA.
Results. The mean age of our series was 60.9 years (SD: 6.5). In a not negligible percentage of patients, the risk group and other
clinical and/or pathological factors could not be determined due to lack of data from referral reports. Before RP, 17.6%, 43.4%,
17% and 22% of patients were classiﬁed into low, intermediate, high or undetermined risk-group, respectively. After RP, 3.1%,
23.9%, 68.6% and 4.4% were deﬁned as low, intermediate, high or undetermined risk-group, respectively. 62.9% of patients had
pT3a-b/T4 tumours and 58.5% had positive surgical margins (unknown: 7.6%). An undetectable level of post-RP PSA (<0.10ng/ml)
was reached by 47.2%, while a permanently detectable-PSA (PD-PSA) ≥0.10ng/ml was present in 42.8% (unknown: 10%). Referral
and corrected EBRT intention were adjuvant (28.9% and 11.9%, respectively) and salvage (71.1% and 88.1%; patients with a PD-PSA
were classiﬁed in salvage-EBRT intention group). Median time from BF to EBRT was 5 months (range: 0–145) and 35.2% had a
pre-EBRT PSA ≥1ng/ml (unknown: 11.9%).
Conclusions. A majority of patients were referred for salvage-EBRT, although most of them met established criteria for adjuvant-
EBRT (pT3a-b/T4 and/or positive margins). In salvage setting, attention should be paid to avoid undue delay in the time from
indication to EBRT referral, not to exceed PSA pre-EBRT described limit of 1ng/ml. High quality data are desirable to a better
decision-making process in this setting.
http://dx.doi.org/10.1016/j.rpor.2013.03.502
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Aim. To report a rare case of primary mucin-producing prostate adenocarcinoma that arise as right pararectal mass and discuss
the clinical diagnosis, treatment and prognosis of the mucin-producing carcinoma of the prostate from a review of published
reports.
Materials and methods. We describe a case of a 74-year-old patient who had 2-month history of urinary frequency and dysuria
that in the last month noticed a gluteal mass without pain. Was initially suspected neoplasm of rectal origin, so various tests
was performed both clinically and immunohistochemically to conﬁrm its origin.
Results. After discarding a neoplasm of rectal origin, this case was diagnosed as a high risk locally advanced prostatic mucin-
producing adenocarcinoma with elevated PSA presenting as a gluteal mass, which was pending to begin long-terms androgen
suppression therapy (2–3 years) plus resection of the mass and external beam radiation therapy. Reviewing the literature, there is
no case with a gluteal mass presentation. Comparing our case with the literature, the primary mucin-producing adenocarcinoma
is a variant of high-grade adenocarcinoma of the prostate with high rate of prostate-speciﬁc antigen elevation.
Conclusions.Mucin-producing adenocarcinomaof theprostate is extremely rare and is aﬁrst casewith a glutealmasspresentation.
Its differential diagnosis mainly includes conventional prostatic adenocarcinoma with mucin production urothelial-type and
secondary adenocarcinoma. The diagnosis and treatment of this disease should be further investigated. Although it has been
suggested that mucinous carcinoma is a variant of high-grade adenocarcinoma of the prostate, and their prognoses are very poor.
http://dx.doi.org/10.1016/j.rpor.2013.03.503
